PTC Therapeutics Competitors and Similar CompaniesClear all
Lannett's competitors and similar companies include ReCode Therapeutics and Ipsen.
 ReCode Therapeutics ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors. | |||
Founding Date | Founding Date 1942 | Founding Date 2015 | Founding Date 1929 |
Type | Type Subsidiary | Type Private | Type Public |
Tags | |||
Locations | Locations Trevose, US HQ Philadelphia, US Seymour, US | Locations Menlo Park, US HQ | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more |
Employees | Employees 484 | Employees 1062% decrease | Employees 5,358 |
Financial | |||
Revenue (est.) | Revenue (est.) $340.6m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) €3.7b (FY, 2025) |
Cost of goods | Cost of goods $294.5m (FY, 2022) | Cost of goods N/A | Cost of goods €659.1m (FY, 2025) |
Gross profit | Gross profit $33.2m (FY, 2022) | Gross profit N/A | Gross profit €3.3b (FY, 2025) |
Net income | Net income ($231.6m) (FY, 2022) | Net income N/A | Net income €445.1m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 28m | Total funding raised $ 82m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ReCode Therapeutics
HQ
Menlo Park, US
Employees
106↓ 2% decrease
ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors.
View company